Edwards Lifesciences Corp has been performing strongly, with
stock outperforming competitors on various trading days. The company has been
upgraded to Buy at Deutsche Bank Aktiengesellschaft. Meanwhile, investors have seen a
respectable return of 50% over the past five years. CEO has shown confidence in the company by buying $49753 in shares. However, the Indian rival, Meril, has
filed an EU antitrust complaint against Edwards, accusing of
anti-competitive behavior. Despite some underperforming days, Edwards' stock jumps of 5.6% and 21.8% year-to-date suggest a growing momentum. It is anticipated by some that
Edwards Lifesciences could beat earnings estimates again. The company has reported
robust Q4 and full-year 2023 financial results, but concerns over negative clinical trial results have impacted the stock. Unexpectedly,
heart valve sales have come up short. Nevertheless, the
stock has rallied by 19%, and the company's
EPS shows acceleration. On a negative note, an
insider has sold 5,000 shares of stock. Despite these events, the company continues to be
controlled by institutional shareholders who own 83% of the company.
Edwards Lifesciences Corp EW News Analytics from Wed, 26 Jul 2023 07:00:00 GMT to Thu, 16 May 2024 16:55:01 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -5
